Get the Stockscreener App
5.4477
2.54%
0.1377
Ironwood Pharmaceuticals Inc stock is traded at $5.4477, with a volume of 2.68M.
It is up +2.54% in the last 24 hours and up +68.58% over the past month.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
See More
Previous Close:
$5.31
Open:
$5.31
24h Volume:
2.68M
Relative Volume:
0.65
Market Cap:
$884.16M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
136.19
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
+20.46%
1M Performance:
+68.58%
6M Performance:
+598.08%
1Y Performance:
+46.37%
1-Day Range:
$5.15
$5.565
1-Week Range:
$4.171
$5.565
52-Week Range:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
5.435 | 863.82M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Zacks Research Issues Optimistic Forecast for IRWD Earnings - MarketBeat
Returns Recap: Can Ironwood Pharmaceuticals Inc. stock double in the next year2025 Earnings Impact & Daily Momentum Trading Reports - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 8.4%Here's Why - MarketBeat
Zacks Research Has Positive Outlook for IRWD Q4 Earnings - MarketBeat
Ironwood Pharma Stock Soars After FDA Grants Approval For Irritable Bowel Syndrome Drug In Pediatric Patients - MSN
Weekly Earnings: Is Ironwood Pharmaceuticals Inc forming a breakout patternJuly 2025 Short Interest & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Aug Weekly: Is Ironwood Pharmaceuticals Inc forming a breakout patternPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5.4%Here's Why - MarketBeat
Insider Sell: Should you avoid Ironwood Pharmaceuticals Inc. stock right nowMarket Sentiment Review & Entry Point Strategy Guides - baoquankhu1.vn
Ironwood Pharmaceuticals (IRWD) Price Target Increased by 94.00% to 4.95 - Nasdaq
Growth Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSWeekly Market Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 10.7%Here's What Happened - MarketBeat
Winners Losers: Is Ironwood Pharmaceuticals Inc affected by consumer sentimentJuly 2025 Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-10 17:20:03 - Улправда
Ironwood Pharma resolves Ferring dispute, amends license terms - MSN
Ironwood stock rises 27% on upbeat revenue guidance for 2026 - MSN
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating - MarketBeat
5 Small Drug Stocks to Buy as Industry Recovery Picks Up - Yahoo Finance
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Craig Hallum - MarketBeat
Why did Ironwood Pharmaceuticals stock skyrocket today? - MSN
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 32% Share Price Rise - 富途牛牛
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st
Citizens Upgrades Ironwood Pharmaceuticals (IRWD) - Nasdaq
Craig-Hallum Boosts Ironwood (IRWD) Rating with Optimistic Outlo - GuruFocus
Wells Fargo Raises Target Price for IRWD to $5.00 Maintaining Eq - GuruFocus
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 - Finviz
Wells Fargo & Company Forecasts Strong Price Appreciation for Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock - MarketBeat
Ironwood Pharmaceuticals Inc. (IRWD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The Five-year Loss for Ironwood Pharmaceuticals (NASDAQ:IRWD) Shareholders Likely Driven by Its Shrinking Earnings - 富途牛牛
Ironwood Pharmaceuticals (IRWD) Upgraded to Market Outperform by Citizens | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) - Benzinga
Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift - TechStock²
Ironwood Pharmaceuticals stock price target raised to $5 by Wells Fargo - Investing.com Canada
Citizens upgrades Ironwood Pharmaceuticals stock rating on LINZESS strength By Investing.com - Investing.com Canada
Promising Pharmaceutical Stocks To ConsiderJanuary 2nd - MarketBeat
Ironwood Pharmaceuticals Surges on Linzess Sales Boost - StocksToTrade
Ironwood Pharmaceuticals’ Stock Surges as Higher Linzess Sales Drive Market Excitement - timothysykes.com
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook - TechStock²
Why Did Ironwood Pharmaceuticals Stock Skyrocket Today? - Asianet Newsable
Ironwood Pharma leaps on 2025/2026 guidance - The Pharma Letter
Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Ironwood Pharmaceuticals: Market Response to Legal Settlement - StocksToTrade
Ironwood Pharma (IRWD) Surges on Strong FY26 Guidance and Pipeli - GuruFocus
Stock soars at Boston biotech after it cuts price of IBS drug - The Business Journals
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):